Gapping down
In reaction to disappointing earnings/guidance:
- ISCA -0.4%
Other news:
- ZYNE -20.9% ( top line results from ZYN001 THC-Prodrug Patch Phase 1 study -- target blood levels of 5 to 15 ng/ml THC were not achieved)
- FIZZ -1.7% (disputes allegations discussed in WSJ article)
Analyst comments:
- N/A.
![]()